Owkin
Alban de La Sablière currently serves as the Chief Operating Officer and Chief Business Officer at Owkin since October 2022. Prior to this role, Alban held various senior positions at Sanofi from January 2016 to October 2022, including Head of Sanofi Partnering, where responsibilities included overseeing a $250 million VC fund, business development and licensing, alliance management, and competitive intelligence, reporting directly to the CEO. Alban also served as Global Head of Business Development & Licensing and Global Head of M&A, playing a key role in revitalizing Sanofi's M&A strategy and executing significant acquisitions and disposals. Previously, from 1997 to December 2015, Alban was a Managing Director and Head of French M&A at Morgan Stanley, providing advisory services on major corporate and private equity M&A transactions. Alban is an alumnus of HEC Paris, graduating between 1992 and 1996.
This person is not in any offices
Owkin
6 followers
Owkin believes that medical research should be collaborative, inclusive, and privacy-preserving. Today, Owkin is pioneering AI in healthcare. It leverages its collaborative federated learning software and expert AI capabilities to bring solutions to optimize drug development and improve patient care in oncology. Owkin’s work has been published in Nature Medicine and other top-tier journals. Owkin has raised over $70M from leading VC funds and is now working with the most prominent cancer centers and pharmaceutical companies in Europe and the US. Additionally, Owkin leads several federated learning consortia, including; MELLODDY, to facilitate 'co-opetive' drug discovery between pharma companies, and Healthchain, to allow collaborative research across multiple hospitals. Owkin was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology, and by Gilles Wainrib, Ph.D., an academic pioneer in the field of Artificial Intelligence in biology.